Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report

Niraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Nevertheless, as of the present moment, there are limited instances demonstrating favorable outcomes stemming from niraparib th...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2024-06, Vol.15, p.1396606
Main Authors: Yue, Xiaolong, Yang, Chenkang, Cao, Dandan, Li, Yue
Format: Article
Language:English
Subjects:
ccRCC
CDK12
niraparib
PARPi
Pharmacology
RAD51C
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Niraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Nevertheless, as of the present moment, there are limited instances demonstrating favorable outcomes stemming from niraparib therapy in patients with clear cell renal cell carcinoma (ccRCC). Here, we report a case of a 50-year-old patient with ccRCC who subsequently developed distant metastasis. The patient received monotherapy with pazopanib and combination therapy with axitinib and tislelizumab, demonstrating limited efficacy. Liquid biopsy revealed missense mutations in the and of the homologous recombination repair (HRR) pathway, suggesting potential sensitivity to PARPi. Following niraparib treatment, the patient's condition improved, with no significant side effects. In summary, patients with ccRCC harboring HRR pathway gene mutation may potentially benefit from niraparib. This will present more options for ccRCC patients with limited response to conventional treatments.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2024.1396606